TINAVI(SH:688277)2025-04-28 15:15Financial Performance - The company reported a revenue of 178.84 million yuan for the reporting period, with a net loss attributable to shareholders of 121.13 million yuan, and a net loss of 169.74 million yuan after deducting non-recurring gains and losses[1]. - The company's operating revenue for 2024 was ¥178.84 million, a decrease of 14.85% compared to ¥210.04 million in 2023[21]. - The net profit attributable to shareholders of the listed company for 2024 was a loss of ¥121.13 million, an improvement from a loss of ¥156.39 million in 2023, representing a 22.54% reduction in losses[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 was a loss of ¥169.74 million, compared to a loss of ¥214.01 million in 2023[21]. - The company reported a significant increase in financial expenses by 140.54% to 7,041,614.45 RMB due to higher borrowing costs[95]. - The company reported a net loss of RMB 121.13 million for the fiscal year 2024, with no distributable profits available for shareholders[171]. Research and Development - Research and development expenses accounted for 65.34% of operating revenue in 2024, a decrease of 6.29 percentage points from 71.63% in 2023[22]. - The company has filed a total of 596 patents, including 232 invention patents, establishing a strong technological barrier in the orthopedic surgical robot field[44]. - The company has developed advanced core technologies, including high-precision online calibration with an error requirement of less than 0.5 mm, enhancing surgical safety and accuracy[70]. - The company has implemented multi-modal medical image fusion and processing technologies to improve surgical planning and execution, ensuring high precision in patient positioning[71]. - The company has achieved a significant increase in capitalized R&D investment, which rose by 208.66% to ¥31,251,363.52, reflecting the successful capitalization of new product development projects[85]. - Cumulative R&D investment over the last three fiscal years amounted to RMB 389.92 million, representing 71.54% of total revenue during that period[174]. Market Position and Strategy - The company aims to continuously expand its market share and accelerate the implementation of application scenarios, focusing on technological innovation and building an ecosystem centered around orthopedic surgical robots[1]. - The company is a leading enterprise in China's orthopedic surgical robot industry and was the first medical robot company to be listed on the Shanghai Stock Exchange's STAR Market in July 2020[56]. - The orthopedic surgical robot market is facing intense competition, and the company is focused on addressing challenges in new product and technology development[47]. - The company is actively pursuing international expansion but may face regulatory challenges that could impact product registration and operational licenses[55]. - The company has established a diversified revenue structure, transitioning from solely equipment sales to include sales of surgical tool kits and ongoing medical technology services[60]. - The orthopedic surgical robot market is projected to expand rapidly, with increasing recognition and acceptance among doctors and patients, leading to a broader customer base beyond first and second-tier cities[67]. Product Development and Innovation - The core product, the "Tianji" orthopedic surgical robot, has completed over 100,000 surgeries across more than 200 medical institutions in China, demonstrating excellent clinical application results[57]. - The company has developed multiple models of orthopedic surgical robots, with the "Tianji 1.0" receiving CFDA certification in 2016 and the "Tianji II" receiving NMPA certification in 2021[57]. - The company has developed an active optical tracking technology that enhances precision, miniaturization, durability, and reliability, which will be used in products launched from 2021 onwards[73]. - The company is focused on continuous innovation and development of its surgical robot technology, ensuring it remains competitive in a rapidly evolving market[66]. - The integration of new technologies such as 5G, AI, and virtual/augmented reality into surgical robots is expected to drive innovation and expand the application range of these devices[67]. Operational Efficiency - The net cash flow from operating activities increased by 42.14% year-on-year, reaching ¥18.07 million in the fourth quarter of 2024[23]. - The company has established a collaborative innovation mechanism with leading universities and hospitals, enhancing its research and development capabilities[41]. - The company is committed to improving the conversion rate of installed hospitals for orthopedic surgical robots and enhancing customer service efficiency[133]. - The company is focused on maintaining a high-quality, low-cost supply chain to ensure the availability of robots and consumables while adhering to regulatory requirements for product development[134]. - The company has implemented a stock incentive plan for 2024, granting 22,343,850 restricted stocks to 74 individuals, which is 21.83% of the total workforce[176]. Corporate Governance and Management - The company maintained strict compliance with corporate governance regulations, ensuring the protection of shareholder interests[137]. - The total pre-tax remuneration for key management personnel amounted to CNY 1,177.12 million for the reporting period[141]. - The remuneration for directors and senior management is composed of salary and bonuses[153]. - The company has not been subject to penalties from securities regulatory agencies in the past three years[155]. - The company held multiple board meetings in 2024 to discuss various proposals, including the use of idle fundraising for liquidity and capital increase for affiliated companies[156]. Environmental Responsibility - The company invested 5.24 million yuan in environmental protection during the reporting period[192]. - The company strictly adheres to national and local environmental protection laws, ensuring pollutant emissions meet relevant standards[194]. - The company promotes energy-saving and resource utilization, advocating a green office model[197]. - The company implements measures to reduce carbon emissions, including prioritizing electric vehicles for administrative use[198].